T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers
associated with oncogenic transformation. This property, which is unique among immune …

Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …

The prokaryote-derived CRISPR–Cas genome editing systems have transformed our ability
to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells …

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …

Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen
receptors (CARs) have shown remarkable clinical responses and are commercially …

Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …

Induced pluripotent stem cells (iPSCs) have strong potential in regenerative medicine
applications; however, immune rejection caused by HLA mismatching is a concern. B2M …